{"protocolSection":{"identificationModule":{"nctId":"NCT03563716","orgStudyIdInfo":{"id":"GO40290"},"secondaryIdInfos":[{"id":"2018-000280-81","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","officialTitle":"A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-08-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-06-30","type":"ACTUAL"},"completionDateStruct":{"date":"2025-08-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-04-17","studyFirstSubmitQcDate":"2018-06-19","studyFirstPostDateStruct":{"date":"2018-06-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-06-19","resultsFirstSubmitQcDate":"2020-06-19","resultsFirstPostDateStruct":{"date":"2020-07-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-28","lastUpdatePostDateStruct":{"date":"2025-07-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":135,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo + Atezolizumab","type":"PLACEBO_COMPARATOR","description":"Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.","interventionNames":["Drug: Atezolizumab","Drug: Placebo"]},{"label":"Tiragolumab + Atezolizumab","type":"EXPERIMENTAL","description":"Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.","interventionNames":["Drug: Atezolizumab","Drug: Tiragolumab"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab","description":"Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.","armGroupLabels":["Placebo + Atezolizumab","Tiragolumab + Atezolizumab"],"otherNames":["Tecentriq"]},{"type":"DRUG","name":"Tiragolumab","description":"Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.","armGroupLabels":["Tiragolumab + Atezolizumab"],"otherNames":["MTIG7192A"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.","armGroupLabels":["Placebo + Atezolizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"ORR, defined as a complete response (CR) or partial response (PR) on two consecutive occasions \\>/=4 weeks apart, as determined by the investigator according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.","timeFrame":"From baseline until a total of 80 progression free survival (PFS) events have occurred (up to approximately 11 months)"},{"measure":"Progression Free Survival (PFS)","description":"PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).","timeFrame":"From baseline until a total of 80 PFS events have occurred (up to approximately 11 months)"}],"secondaryOutcomes":[{"measure":"Duration of Objective Response (DOR)","description":"DOR, defined as the time from the first occurrence of a documented objective response (CR or PR) to disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).","timeFrame":"Up to 6 years"},{"measure":"Overall Survival (OS)","description":"OS, defined as the time from randomization to death from any cause.","timeFrame":"Up to 6 years"},{"measure":"Percentage of Participants With Adverse Events","description":"An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","timeFrame":"Up to 6 years"},{"measure":"Serum Concentrations of Tiragolumab","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)"},{"measure":"Serum Concentrations of Atezolizumab","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)"},{"measure":"Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ECOG Performance Status of 0 or 1\n* Histologically or cytologically documented locally advanced unresectable NSCLC, recurrent, or metastatic NSCLC of either squamous or non-squamous histology\n* No prior systemic treatment for locally advanced unresectable or metastatic NSCLC\n* Tumor PD-L1 expression\n* Measurable disease, as defined by RECIST v1.1\n* Life expectancy \\>=12 weeks\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm\n\nExclusion Criteria:\n\nCancer-Specific Exclusions:\n\n* Patients with NSCLC known to have a sensitizing mutation in the EGFR gene or an ALK fusion oncogene\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Spinal cord compression not definitively treated with surgery and/or radiation, and/or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\>=2 weeks prior to screening\n* History of leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled tumor-related pain\n* Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome\n\nGeneral Medical Exclusions:\n\n* Pregnant and lactating women\n* Significant cardiovascular disease\n* Severe infections within 4 weeks prior to randomization\n* Major surgical procedure other than for diagnosis within 4 weeks prior to randomization\n\nTreatment-Specific Exclusions:\n\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease\n* Prior allogeneic bone marrow transplantation or solid organ transplantation\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or active tuberculosis\n* Administration of a live, attenuated vaccine within 4 weeks prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Arizona Oncology Associates, PC - HAL","city":"Tempe","state":"Arizona","zip":"85284","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"SCRI Florida Cancer Specialists South","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Florida Cancer Specialists - NORTH - SCRI - PPDS","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Illinois Cancer Specialists","city":"Arlington Heights","state":"Illinois","zip":"60005","country":"United States","geoPoint":{"lat":42.08836,"lon":-87.98063}},{"facility":"Illinois Cancer Care","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"University of Kansas Medical Center","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.04056,"lon":-94.6169}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"HCA Midwest Health","city":"Kansas City","state":"Missouri","zip":"64132","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Virginia Cancer Specialists, PC","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Northwest Cancer Specialists - Vancouver","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"ICO Paul Papin","city":"Angers","zip":"49055","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Centre Georges François Leclerc","city":"Dijon","zip":"21079","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Hopital Nord AP-HM","city":"Marseille","zip":"13015","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Institut De Cancerologie De L'Ouest","city":"Saint-Herblain","zip":"44115","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"Clinical Center of Serbia","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Hospital Center Bezanijska Kosa","city":"Belgrade","zip":"11070","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Chungbuk National University Hospital","city":"Cheongju-si","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Seoul National University Bundang Hospital","city":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Kangbuk Samsung Hospital","city":"Seoul","zip":"03181","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Univ Germans Trias i Pujol","city":"Badalona","state":"Barcelona","zip":"8916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Complejo Hospitalario Universitario Insular?Materno Infantil","city":"Las Palmas de Gran Canaria","state":"LAS Palmas","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Clinica Universitaria de Navarra","city":"Pamplona","state":"Navarre","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hospital General Universitario de Alicante","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Universitario Vall d'Hebron - PPDS","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Clinica Universitaria Navarra (Madrid)","city":"Madrid","zip":"28036","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Puerta de Hierro - Majadahonda","city":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Centro Medico Quironsalud Sagrado Corazon","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Taipei Medical University ?Shuang Ho Hospital","city":"New Taipei City","zip":"23561","country":"Taiwan","geoPoint":{"lat":25.06199,"lon":121.45703}},{"facility":"National Cheng Kung University Hospital","city":"North Dist.","zip":"70403","country":"Taiwan"},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"1121","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Chang Gung Memorial Hospital - Linkou","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}}]},"referencesModule":{"references":[{"pmid":"38418879","type":"DERIVED","citation":"Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28."},{"pmid":"35576957","type":"DERIVED","citation":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible patients with previously untreated, locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) were randomized 1:1 to receive either placebo plus atezolizumab or tiragolumab plus atezolizumab.","recruitmentDetails":"Participants were recruited at study sites in 6 countries.","groups":[{"id":"FG000","title":"Placebo + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle."},{"id":"FG001","title":"Tiragolumab + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"COMPLETED","comment":"Study still on-going","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","comment":"One participant who died had as reason for discontinuation \"Withdrawal by Subject\"","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"67"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Still on Study","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"50"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle."},{"id":"BG001","title":"Tiragolumab + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"135"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.0","spread":"9.9"},{"groupId":"BG001","value":"65.8","spread":"10.4"},{"groupId":"BG002","value":"66.4","spread":"10.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"48"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"87"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"123"}]},{"title":"Not Stated","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Asian","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"41"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"82"}]},{"title":"Multiple","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"ORR, defined as a complete response (CR) or partial response (PR) on two consecutive occasions \\>/=4 weeks apart, as determined by the investigator according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.","populationDescription":"Intent-to-Treat (ITT) population included all participants randomized in the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From baseline until a total of 80 progression free survival (PFS) events have occurred (up to approximately 11 months)","groups":[{"id":"OG000","title":"Placebo + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle."},{"id":"OG001","title":"Tiragolumab + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","lowerLimit":"6.69","upperLimit":"25.66"},{"groupId":"OG001","value":"31.3","lowerLimit":"19.49","upperLimit":"43.20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratified analysis based on PD-L1 immunohistochemistry (IHC) 22C3 pharmDx, tumor histology status, and tobacco history.","nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"2.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.07","ciUpperLimit":"6.14","estimateComment":"95% CI for odds ratio was constructed using the Wald method."}]},{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).","populationDescription":"ITT population included all participants randomized in the study.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline until a total of 80 PFS events have occurred (up to approximately 11 months)","groups":[{"id":"OG000","title":"Placebo + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle."},{"id":"OG001","title":"Tiragolumab + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","lowerLimit":"2.73","upperLimit":"4.44"},{"groupId":"OG001","value":"5.42","lowerLimit":"4.21","upperLimit":"NA","comment":"95% Confidence Interval (CI) was not estimable as participants without documentation of progressive disease (PD) were censored."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratified analysis based on PD-L1 IHC 22C3 pharmDx, tumor histology status, and tobacco history.","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.37","ciUpperLimit":"0.90","estimateComment":"Hazard ratios were estimated by Cox regression."}]},{"type":"SECONDARY","title":"Duration of Objective Response (DOR)","description":"DOR, defined as the time from the first occurrence of a documented objective response (CR or PR) to disease progression (PD), as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline).","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Up to 6 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS, defined as the time from randomization to death from any cause.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Up to 6 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Up to 6 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Serum Concentrations of Tiragolumab","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Serum Concentrations of Atezolizumab","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2026-03","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 12 Day 1 (each cycle is 21 days)","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to primary completion date (approximately 11 months)","description":"The safety population included all participants who received at least one dose of study medication.","eventGroups":[{"id":"EG000","title":"Placebo + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.","deathsNumAffected":20,"deathsNumAtRisk":68,"seriousNumAffected":24,"seriousNumAtRisk":68,"otherNumAffected":58,"otherNumAtRisk":68},{"id":"EG001","title":"Tiragolumab + Atezolizumab","description":"Participants received atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.","deathsNumAffected":15,"deathsNumAtRisk":67,"seriousNumAffected":23,"seriousNumAtRisk":67,"otherNumAffected":60,"otherNumAtRisk":67}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Adrenal haemorrhage","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Cytomegalovirus colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Epstein-Barr virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pleural infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":67}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pericardial effusion malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Autoimmune nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pelvic venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":68},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":67}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":67}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":68},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":67}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":68},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":67}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":67}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":68},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":67}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":68},{"groupId":"EG001","numEvents":18,"numAffected":15,"numAtRisk":67}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":68},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":67}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":68},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":67}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":68},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":67}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":7,"numAtRisk":68},{"groupId":"EG001","numEvents":22,"numAffected":18,"numAtRisk":67}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":68},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":67}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":67}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":67}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":67}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":67}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":68},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":67}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":67}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":68},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":67}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":67}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":67}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":67}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":67}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":68},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":67}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":68},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":67}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":68},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":67}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":68},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":67}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":68},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":67}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":68},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":67}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":68},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":67}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":68},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":67}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":68},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":67}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":68},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":67}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-02-06","uploadDate":"2020-06-19T14:23","filename":"Prot_SAP_000.pdf","size":6966174}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Brazil","Poland","Romania"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"},{"id":"C000730814","term":"Tiragolumab"}]}},"hasResults":true}